Blockade of KCa3.1 ameliorates renal fibrosis through the tgf-β1/smad pathway in diabetic mice

Diabetes

Volumn 62, Issue 8, 2013, Pages 2923-2934

  Huang, Chunling ^a,b   Shen, Sylvie ^a   Ma, Qing ^a   Chen, Jason ^c   Gill, Anthony ^c   Pollock, Carol A ^a   Chen, Xin Ming ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b XIAMEN UNIVERSITY   (China)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; ALBUMIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ACTIVATED POTASSIUM CHANNEL KCA3.1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; KCNN4 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ALBUMIN CREATININE RATIO; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL SYSTEM PARAMETERS; SIGNAL TRANSDUCTION; UPREGULATION; WEIGHT GAIN; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; FIBROSIS; GENETICS; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; ANTAGONISTS AND INHIBITORS; DIABETIC NEPHROPATHIES; DRUG EFFECTS;

ANIMALS; CHEMOKINE CCL2; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBROSIS; HUMANS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; KIDNEY; MICE; MICE, KNOCKOUT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRAZOLES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84885407930     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0135     Document Type: Article

References (35)

1. Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011;22:545-553
2. Zheng H, Whitman SA, Wu W, et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011;60: 3055-3066
3. Wolf G. Growth factors and the development of diabetic nephropathy. Curr Diab Rep 2003;3:485-490
4. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007;87:1077-1091
5. Ruster C, Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci 2008;13:944-955
6. Stocker M. Ca(2+)-Activated K+ channels: molecular determinants and function of the SK family. Nat Rev Neurosci 2004;5:758-770
7. Gardos G. The function of calcium in the potassium permeability of human erythrocytes. Biochim Biophys Acta 1958;30:653-654
8. Joiner WJ, Wang LY, Tang MD, Kaczmarek LK. hSK4, a member of a novel subfamily of calcium-Activated potassium channels. Proc Natl Acad Sci USA 1997;94:11013-11018
9. Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, Maylie J. A human intermediate conductance calcium-Activated potassium channel. Proc Natl Acad Sci USA 1997;94:11651-11656
10. Logsdon NJ, Kang J, Togo JA, Christian EP, Aiyar J. A novel gene, hKCa4, encodes the calcium-Activated potassium channel in human T lymphocytes. J Biol Chem 1997;272:32723-32726
11. Begenisich T, Nakamoto T, Ovitt CE, et al. Physiological roles of the intermediate conductance, Ca2+-Activated potassium channel Kcnn4. J Biol Chem 2004;279:47681-47687
12. Chou CC, Lunn CA, Murgolo NJ. KCa3.1: Target and marker for cancer, autoimmune disorder and vascular inflammation? Expert Rev Mol Diagn 2008;8:179-187
13. Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes. J Immunol 2007;179:4563-4570
14. Tao R, Lau CP, Tse HF, Li GR. Regulation of cell proliferation by intermediateconductance Ca2+-Activated potassium and volume-sensitive chloride channels in mouse mesenchymal stem cells. Am J Physiol Cell Physiol 2008;295: C1409-C1416
15. Tharp DL, Bowles DK. The intermediate-conductance Ca2+ -Activated K+ channel (KCa3.1) in vascular disease. Cardiovasc Hematol Agents Med Chem 2009;7:1-11
16. Toyama K, Wulff H, Chandy KG, et al. The intermediate-conductance calcium-Activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest 2008;118:3025-3037
17. Köhler R, Wulff H, Eichler I, et al. Blockade of the intermediate-conductance calcium-Activated potassium channel as a new therapeutic strategy for restenosis. Circulation 2003;108:1119-1125
18. Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, Shakkottai V. Modulators of small- and intermediate-conductance calcium-Activated potassium channels and their therapeutic indications. Curr Med Chem 2007;14: 1437-1457
19. Ohya S, Kimura K, Niwa S, et al. Malignancy grade-dependent expression of K+-channel subtypes in human prostate cancer. J Pharmacol Sci 2009; 109:148-151
20. Wulff H, Gutman GA, Cahalan MD, Chandy KG. Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-Activated potassium channel, IKCa1. J Biol Chem 2001;276:32040-32045
21. Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, Chandy KG. Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-Activated K+ channel, IKCa1: A potential immunosuppressant. Proc Natl Acad Sci USA 2000;97:8151-8156
22. Grgic I, Kiss E, Kaistha BP, et al. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci USA 2009; 106:14518-14523
23. Grgic I, Wulff H, Eichler I, Flothmann C, Köhler R, Hoyer J. Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc 2009;41:2601-2606
24. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 2007;12:261-266
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408
26. Doi S, Zou Y, Togao O, et al. Klotho inhibits transforming growth factorbeta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011;286:8655-8665
27. Brosius FC 3rd, Alpers CE, Bottinger EP, et al.; Animal Models of Diabetic Complications Consortium. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009;20:2503-2512
28. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006;69:213-217
29. Ghanshani S, Wulff H, Miller MJ, et al. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 2000;275:37137-37149
30. Cruse G, Duffy SM, Brightling CE, Bradding P. Functional KCa3.1 K+ channels are required for human lung mast cell migration. Thorax 2006;61:880-885
31. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 2004;18:176-178
32. Wulff H, Calabresi PA, Allie R, et al. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest 2003;111: 1703-1713
33. Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD. K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci 2004;25:280-289
34. Isono M, Chen S, Hong SW, Iglesias-de la Cruz MC, Ziyadeh FN. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 2002;296:1356-1365
35. Huang Y, Noble NA. PAI-1 as a target in kidney disease. Curr Drug Targets 2007;8:1007-1015